Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, has made an additional investment in a venture company that utilizes research results from Kyoto University. (Head office: Sakyo-ku, Kyoto; Representative Director: Teruo Susumu), a venture company that utilizes research results from Kyoto University.

Execution of investment in 0aceRNA
aceRNA is a company engaged in the purification of regenerative cellular medicines and drug discovery business through its platform technology using artificial RNA molecules ("RNA Switch") developed by Hirohide Saito, Deputy Director of the Kyoto University iPS Cell Research Institute.

Pluripotent stem cells such as iPS cells and ES cells are used as regenerative cell medicine after undergoing a differentiation process. Since undifferentiated stem cells remaining in the differentiation process may cause cancer, a technology to remove undifferentiated stem cells is required for the practical use of iPS and ES cells. RNA switches are expected to contribute to medicine as an important technology to improve the safety and quality of regenerative cell medicines.

aceRNA has previously launched RNA Switch™, a reagent for purification of iPS-derived cells and differentiated cardiomyocytes (https://acernatec.com/product/In research and development, we have completed a library corresponding to all types of miRNAs expressed in humans and have begun identification of new drug targets.

Kyoto iCAP expects that our technology will continue to contribute to improving the safety of regenerative cell medicine and identifying drug targets, and has participated in a total of 200 million yen in financing together with SMBC Venture Capital Co. (Head office: Chuo-ku, Tokyo; President: Tatsushi Ishibashi) and several individual investors.

aceRNA Technologies, Inc.

Establishment	April 2018
Business	Development of cell purification products and drug discovery using RNA switch technology
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Teruo Shin